SCHEMBL5690648

SCHEMBL5690648

O=C(O)c1ccc(OCC2CCN(C(=O)Oc3ccc(CSc4ncc[nH]4)cc3)CC2)cc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD11B1 P28845 1/20 0.41
HDAC1 Q13547 2/20 0.40
ALDH1A1 P00352 1/20 0.39
CYP1A2 P05177 1/20 0.39
CYP2E1 P05181 1/20 0.39
CYP3A4 P08684 1/20 0.39
CYP2C8 P10632 1/20 0.39
CYP2D6 P10635 1/20 0.39
CYP2C9 P11712 1/20 0.39
CYP2B6 P20813 1/20 0.39
CYP2C19 P33261 1/20 0.39
CYP4F2 P78329 1/20 0.38
CYP4A11 Q02928 1/20 0.38
CHEK2 O96017 3/20 0.38
GRIN2B Q13224 3/20 0.38
SSTR5 P35346 1/20 0.37
KCNH2 Q12809 1/20 0.37
HTR2B P41595 1/20 0.37
GRIN2A Q12879 1/20 0.37
NPC1 O15118 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5687404 0.91 HSD11B1 (0.44) HSD11B1HDAC1CYP4F2CYP4A11CHEK2
SCHEMBL5687411 0.91 HSD11B1 (0.41) HSD11B1HDAC1CYP4F2CYP4A11CHEK2
SCHEMBL5687804 0.88 SRD5A2 (0.44) HSD11B1HDAC1ALDH1A1CYP1A2CYP2E1
SCHEMBL5688719 0.86 HSD11B1 (0.46) HSD11B1HDAC1ALDH1A1GRIN2BHTR2B
SCHEMBL5687738 0.85 LIPE (0.44) HSD11B1HDAC1CYP4F2CYP4A11GRIN2B
SCHEMBL5931853 0.83 LIPE (0.46) HSD11B1CYP4F2CYP4A11GRIN2B
SCHEMBL5690501 0.83 GPR119 (0.40) HSD11B1CYP4F2CYP4A11CHEK2
SCHEMBL5690231 0.82 HSD11B1 (0.44) HSD11B1CYP4F2CYP4A11GRIN2BGRIN2A
SCHEMBL5688814 0.82 HSD11B1 (0.40) HSD11B1HDAC1CYP4F2CYP4A11GRIN2B
SCHEMBL5691207 0.82 HSD11B1 (0.41) HSD11B1HDAC1ALDH1A1CYP1A2CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060160851-A1 Substituted piperidine carbamates NOVO NORDISK A/S (DK) 2006-07-20 US claimed
EP-1636207-A1 SUBSTITUTED PIPERIDINE CARBAMATES FOR USE AS INHIBITORS OF HORMONE SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2006-03-22 EP claimed
WO-2004111032-A1 SUBSTITUTED PIPERIDINE CARBAMATES FOR USE AS INHIBITORS OF HORMONE SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2004-12-23 WO claimed
US-20060160851-A1 Substituted piperidine carbamates NOVO NORDISK A/S (DK) 2006-07-20 US disclosed
EP-1636207-A1 SUBSTITUTED PIPERIDINE CARBAMATES FOR USE AS INHIBITORS OF HORMONE SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2006-03-22 EP disclosed
WO-2004111032-A1 SUBSTITUTED PIPERIDINE CARBAMATES FOR USE AS INHIBITORS OF HORMONE SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2004-12-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060160851-A1 Substituted piperidine carbamates LIPE, PNLIP, LIPC HSD11B1 1283/4885HDAC1 161/4885ALDH1A1 1044/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.